Temporal trends in the proportion of “cure” in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: A population‐based study

Drozdov, Daniel; Bonaventure, Audrey; Nakata, Kayo; Suttorp, Meinolf; Belot, Aurélien

doi:10.1002/pbc.27422

Cited by 10 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The introduction of (life-long) tyrosine kinase inhibitor treatment, which specifically targets BCR-ABL, often found in CML patients, likely also resulted in the high survival gains and favourable outcomes that were observed for all CML patients at AYA age in this study [9,13,63].…”

Section: Chronic Myeloid Leukaemiamentioning

confidence: 87%

Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016

Meer

Karim‐Kos

Mark

et al. 2020

Cancers

View full text Add to dashboard Cite

Adolescent and young adult (AYA) cancer patients, aged 15–39 years at primary cancer diagnosis, form a distinct, understudied, and underserved group in cancer care. This study aimed to assess long-term trends in incidence, survival, and mortality of AYA cancer patients within the Netherlands. Data on all malignant AYA tumours diagnosed between 1990–2016 (n = 95,228) were obtained from the Netherlands Cancer Registry. European age-standardised incidence and mortality rates with average annual percentage change (AAPC) statistics and five-year relative survival rates were calculated. The overall cancer incidence increased from 54.6 to 70.3 per 100,000 person-years (AAPC: +1.37%) between 1990–2016, and increased for both sexes individually and for most cancer types. Five-year relative survival overall improved from 73.7% in 1990–1999 to 86.4% in 2010–2016 and improved for both sexes and most cancer types. Survival remained poor (<60%) for rhabdomyosarcoma, lung, stomach, liver, bladder, and pancreatic carcinomas, among others. Mortality rates among male AYAs overall declined from 10.8 to 6.6 (AAPC: −1.64%) and from 14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) for female AYAs since 1990. Mortality rates remained unchanged for male AYAs aged 20–24 and 25–29 years. In conclusion, over the past three decades, there has been a considerable increase in cancer incidence among AYAs in the Netherlands. Meanwhile, the survival improved and the mortality overall declined. Survival at five-years now well exceeds above 80%, but did not do so for all cancer types.

show abstract

Section: Chronic Myeloid Leukaemiamentioning

confidence: 87%

Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016

Meer

Karim‐Kos

Mark

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In the first two decades of life, CML is exceptionally rare in infancy, reportedly 0.7/million/year at age between 1 and 14 years, and rising to 1.2/million/year in adolescents. 4,5 A few studies have focused on clinical and biological data of CML at pediatric and adolescent ages. 6,7 In the largest trials so far on pediatric CML (CML-paed-I, CML-paed-II), only two and three patients, respectively, were younger than 3 years at diagnosis.…”

Section: Introductionmentioning

confidence: 99%

“…As the incidence of CML increases with age, some of these variations are due to significant differences in the age distributions of the investigated populations (eg, Western vs non‐Western countries, age range of pediatric cohorts 0‐14 years, 0‐16 years, or 0‐18 years). In the first two decades of life, CML is exceptionally rare in infancy, reportedly 0.7/million/year at age between 1 and 14 years, and rising to 1.2/million/year in adolescents 4,5 . A few studies have focused on clinical and biological data of CML at pediatric and adolescent ages 6,7 .…”

Section: Introductionmentioning

confidence: 99%

Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry

Güneş

Millot²,

Kałwak

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Introduction: Chronic myeloid leukemia (CML) is rare in the first two decades of life comprising only 3% of newly diagnosed pediatric and adolescent leukemias. We studied the epidemiologic and clinical features of patients with CML diagnosed at younger than 3 years of age and evaluated treatment and long-term outcome. Method: Data from the International Pediatric I-BFM/CML Registry were retrospectively analyzed using the European LeukemiaNet criteria of the year 2006. Characteristics and treatment outcome of patients <3 years old at diagnosis were evaluated from standardized forms. Results: Twenty-two patients (n = 22/479; 4.6%, male/female:14/8) were enrolled with a median age of 22 months (range, 10-34 m). Major symptoms comprised asthenia (30%), fever (30%), abdominal pain (20%), extramedullary signs (14%), hemorrhage (5%), and weight loss (5%). The extramedullary signs were specified in eight children: blueberry muffin (n = 1), sudden swollen abdomen (n = 1), sustained vomiting (n = 1), and cervical and inguinal lymph nodes (n = 5). Two of five children with cervical and inguinal lymph nodes were categorized as accelerated phase. Overall, 19 of 22 (86%) children were diagnosed in chronic phase, while the remaining three patients were in advanced phase. Median follow-up was 78 months (range, 7-196 m). Twenty-one out of 22 patients initially received imatinib, while one child received IFN + ARA-C. Imatinib was changed to second-line tyrosine kinase inhibitors (TKIs) in 29% of cases. During follow-up, 41% patients underwent stem cell transplantation (SCT). While on TKI, major molecular response (MMR) was achieved in 48% of children. Among the remaining patients, 21% are alive on TKI without MMR and 22% achieved complete molecular response following SCT. Twenty-one of 22 (95%) children are alive, while one patient died of posttransplant complications.

show abstract

“…Were the tests ordered as part of routine clinical care? The study design needs clarification.Instead of reporting 100% sensitivity "among the patients with HM and confirmed infections", I would prefer to (also) see the "overall agreement" of 70% with standard micro methods.There is limited data on Karius performance for invasive mold infections, and the authors should acknowledge that, referring to additional studies, specifically DMID 2018;92:210 1 (7 of 9 pts correctly identified), Pediatr Blood Cancer 2018;66:e27734 2 (4 of 6 pts correctly identified).…”

mentioning

confidence: 99%

“…There is limited data on Karius performance for invasive mold infections, and the authors should acknowledge that, referring to additional studies, specifically DMID 2018;92:210 1 (7 of 9 pts correctly identified), Pediatr Blood Cancer 2018;66:e27734 2 (4 of 6 pts correctly identified).…”

mentioning

confidence: 99%

Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts

Camargo

Ahmed²,

Morris

et al. 2019

F1000Res

View full text Add to dashboard Cite

Background: Cell-free DNA (cfDNA) sequencing has emerged as an effective laboratory method for rapid and noninvasive diagnosis in prenatal screening testing, organ transplant rejection screening, and oncology liquid biopsies but clinical experience for use of this technology in diagnostic evaluation of infections in immunocompromised hosts is limited. Methods: We conducted an exploratory study using next-generation sequencing (NGS) for detection of microbial cfDNA in a cohort of ten immunocompromised patients with febrile neutropenia, pneumonia or intra-abdominal infection. Results: Pathogen identification by cfDNA NGS demonstrated positive agreement with conventional diagnostic laboratory methods in 7 (70%) cases, including patients with proven/probable invasive aspergillosis, Pneumocystis jirovecii pneumonia, Stenotrophomonas maltophilia bacteremia, Cytomegalovirus and Adenovirus viremia. NGS results were discordant in 3 (30%) cases including two patients with culture negative sepsis who had undergone hematopoietic stem cell transplant in whom cfDNA testing identified the etiological agent of sepsis; and one kidney transplant recipient with invasive aspergillosis who had received >6 months of antifungal therapy prior to NGS testing. Conclusion: These observations support the clinical utility of measurement of microbial cfDNA sequencing from peripheral blood for rapid noninvasive diagnosis of infections in immunocompromised hosts. Larger studies are needed.

show abstract

Temporal trends in the proportion of “cure” in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: A population‐based study

Cited by 10 publications

References 34 publications

Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016

Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016

Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry

Next-generation sequencing of microbial cell-free DNA for rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts

Contact Info

Product

Resources

About